Cancer-Related Causes of Death among HIV-Infected Patients in France in 2010: Evolution since 2000

Vandenhende, Marie-Anne; Roussillon, Caroline; Hénard, S.; Morlat, Philippe; Oksenhendler, Éric; Aumaître, Hugues; Georget, Aurore; May, Thierry; Rosenthal, Éric; Salmon, Dominique; Cacoub, Patrice; Costagliola, Dominique; Chêne, Geneviève; Bonnet, Fabrice

doi:10.1371/journal.pone.0129550

Cited by 78 publications

(70 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A lthough AIDS-defining cancers have declined following the introduction of combined antiretroviral therapy (cART), non-Hodgkin lymphomas (NHLs) still comprise more than 50% of all AIDS-defining cancers (1) and are the most frequent cause of death in these patients (2). Most HIV-1-related NHLs (HIV-NHLs) are high-grade B-cell lymphomas such as diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL).…”

Section: B-cell Clonogenicitymentioning

confidence: 99%

Role of HIV-1 matrix protein p17 variants in lymphoma pathogenesis

Dolcetti

Giagulli

et al. 2015

Proc. Natl. Acad. Sci. U.S.A.

102

View full text Add to dashboard Cite

Although in decline after successful anti-HIV therapy, B-cell lymphomas are still elevated in HIV-1-seropositive (HIV+) persons, and the mechanisms are obscure. The HIV-1 matrix protein p17 persists in germinal centers long after HIV-1 drug suppression, and some p17 variants (vp17s) activate Akt signaling and promote growth of transformed B cells. Here we show that vp17s derived from four of five non-Hodgkin lymphoma (NHL) tissues from HIV+ subjects display potent B-cell growth-promoting activity. They are characterized by amino acid insertions at position 117-118 (Ala-Ala) or 125-126 (Gly-Asn or Gly-Gln-Ala-Asn-Gln-Asn) among some other mutations throughout the sequence. Identical dominant vp17s are found in both tumor and plasma. Three of seven plasma samples from an independent set of NHL cases manifested multiple Ala insertions at position 117-118, and one with the Ala-Ala profile also promoted B-cell growth and activated Akt signaling. Ultradeep pyrosequencing showed that vp17s with C-terminal insertions are more frequently detected in plasma of HIV+ subjects with than without NHL. Insertion of Ala-Ala at position 117-118 into reference p17 (refp17) was sufficient to confer B-cell growth-promoting activity. In contrast, refp17 bearing the Gly-Asn insertion at position 125-126 did not, suggesting that mutations not restricted to the C terminus can also account for this activity. Biophysical analysis revealed that the Ala-Ala insertion mutant is destabilized compared with refp17, whereas the Gly-Asn form is stabilized. This finding provides an avenue for further exploration of structure function relationships and new treatment strategies in combating HIV-1-related NHL.non-Hodgkin lymphoma | HIV-1 matrix protein p17 | AIDS | p17 variants | B-cell clonogenicity

show abstract

Section: B-cell Clonogenicitymentioning

confidence: 99%

Role of HIV-1 matrix protein p17 variants in lymphoma pathogenesis

Dolcetti

Giagulli

et al. 2015

Proc. Natl. Acad. Sci. U.S.A.

102

View full text Add to dashboard Cite

show abstract

“…9,10 This is largely because HIV increases the risk of some cancers, the prevalence of HIV increases with improved life expectancy, and the population of people living with HIV is aging. The cancers most closely linked to HIV 11,12 comprise approximately two thirds of cancers in this population.…”

Section: Introductionmentioning

confidence: 99%

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology–Friends of Cancer Research HIV Working Group

Uldrick

Ison

Rudek

et al. 2017

JCO

127

View full text Add to dashboard Cite

Purpose People with HIV are living longer as a result of effective antiretroviral therapy. Cancer has become a leading cause of morbidity and mortality in this patient population. However, studies of novel cancer therapeutics have historically excluded patients with HIV. Critical review of eligibility criteria related to HIV is required to accelerate development of and access to effective therapeutics for HIV-infected patients with cancer and make studies more generalizable to this patient population. Methods From January through April 2016, the HIV Working Group conducted a series of teleconferences; a review of 46 New Drug Applications from registration studies of unique agents studied in adults with cancer that led to the initial US Food and Drug Administration approval of that agent from 2011 to 2015; and a review of HIV-related eligibility criteria from National Cancer Institute–sponsored studies. Results were discussed and refined at a multistakeholder workshop held May 12, 2016. The HIV Working Group developed recommendations for eligibility criteria that focus on pharmacologic and immunologic considerations in this patient population and that balance patient safety, access to appropriate investigational agents, and study integrity. Results Exclusion of patients with HIV remains common in most studies of novel cancer agents. Models for HIV-related eligibility criteria in National Cancer Institute–sponsored studies are instructive. HIV infection itself should no longer be an exclusion criterion for most studies. Eligibility criteria related to HIV infection that address concurrent antiretroviral therapy and immune status should be designed in a manner that is appropriate for a given cancer. Conclusion Expanding clinical trial eligibility to be more inclusive of patients with HIV is justified in most cases and may accelerate the development of effective therapies in this area of unmet clinical need.

show abstract

“…Among PLWH, smoking is associated with poor health (Freiberg et al, 2010; Madeddu et al, 2013; Vandenhende et al, 2015), poor adherence to and decreased effectiveness of antiretroviral therapy, and poor HIV treatment outcomes (Feldman et al, 2006; O’Cleirigh et al, 2015; Shuter & Bernstein, 2008). Smokers with HIV lose more life years to smoking than to HIV (Helleberg et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

Positive smoking cessation-related interactions with HIV care providers increase the likelihood of interest in cessation among HIV-positive cigarette smokers

2017

View full text Add to dashboard Cite

Smoking cessation has proven to be a challenge for HIV-positive smokers. Patient and provider characteristics may provide barriers to smoking cessation. We aimed to identify characteristics associated with interest in cessation as well as characterize use of, current interest in, and provider recommendations for smoking cessation modalities. Data came from 275 HIV-positive smokers recruited online. Half (49.1%) of the sample was interested in quitting; daily smoking was associated with decreased likelihood of interest in cessation, whereas making a lifetime quit attempt, receiving encouragement to quit from an HIV care provider, and greater frequency of discussions regarding cessation with HIV care providers were associated with increased likelihood of interest in cessation. Nicotine replacement therapy was the most commonly used (42.9%), generated the most interest (59.1%), and was the most commonly clinician-recommended (70.7%) cessation modality. Findings emphasize the importance of the healthcare provider-patient relationship for smoking cessation promotion in HIV-positive smokers.

show abstract

Cancer-Related Causes of Death among HIV-Infected Patients in France in 2010: Evolution since 2000

Cited by 78 publications

References 38 publications

Role of HIV-1 matrix protein p17 variants in lymphoma pathogenesis

Role of HIV-1 matrix protein p17 variants in lymphoma pathogenesis

Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology–Friends of Cancer Research HIV Working Group

Positive smoking cessation-related interactions with HIV care providers increase the likelihood of interest in cessation among HIV-positive cigarette smokers

Contact Info

Product

Resources

About